Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive

HIV Medicine

Volumn 6, Issue 4, 2005, Pages 260-267

  Bergersen, B M ^a   Sandvik, L ^a   Ellingsen, I ^a   Bruun, J N ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiretroviral therapy; Blood pressure; HIV; Hypertension; Lipoatrophy; Stavudine

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; CAUCASIAN; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SKINFOLD; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 22644434360     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00305.x     Document Type: Article

References (38)

1. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
2. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.
3. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-1046.
4. Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811-1822.
5. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
6. Bogner JR, Vielhauer V, Beckmann RA et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001; 27: 237-244.
7. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-979.
8. Joly V, Flandre P, Meiffredy V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16: 2447-2454.
9. Lichtenstein KA, Delaney KM, Armon C et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48-56.
10. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-28.
11. John M, McKinnon EJ, James IR et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 29-33.
12. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
13. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731-736.
14. Bergersen BM, Sandvik L, Bruun JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004; 36: 186-191.
15. Bergersen BM, Tonstad S, Sandvik L, Bruun J. Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/l in non-nucleoside reverse transcriptase inhibitor recipients. Int J STD AIDS 2005; 16: 365-369.
16. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbial Infect Dis 2004; 23: 625-630.
17. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Campaign, IL, Human kinetics books, 1988.
18. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
19. Norwegian Institute of Public Health Main Questionnaire Oslo Health Study 2000-01 (HUBRO). http://www.fhi.no/dav/66091FDE33734FAB96849B26D9F46333.pdf
20. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-735.
21. Castro KG, Ward JW, Slutsker L et al. Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Atlanta, GA: National Center for Infectious Disease, Division of HIV/AIDS, Centers for Disease Control and Prevention, 1993.
22. Kran AM, Sorensen B, Nyhus J et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004; 18: 1875-1883.
23. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-1036.
24. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-510.
25. Brinkman Y, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
26. Bastard JP, Caron M, Vidal H et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-1031.
27. Mynarcik DC, McNurlan AM, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312-321.
28. Nolan D, Moore C, Castley A et al. Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17: 121-123.
29. Chow D, Souza S, Richmond-Crum S, Shikuma C. Epidemiological evidence of increasing blood pressure in HIV-1-infected individuals in the era of HAART. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13-15th September 2000. Antiviral Ther 2000; 5 (Suppl. 5): 31-32, [Abstract P13].
30. Bergersen BM, Moss L, Sannes M, Bruun J. Different systolic blood pressure in HIV infected patients with and without antiretroviral therapy. 2nd Workshop of Lipodystrophy Cannes, France, April 2001 [Abstract P21].
31. Sattler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15: 2001-2010.
32. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.
33. Sandvik L, Erikssen G, Thaulow E. Long term effects of smoking on physical fitness and lung function: a longitudinal study of 1393 middle aged Norwegian men for seven years. Br Med J 1995; 311: 715-718.
34. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4: 411-416.
35. Seaberg EC, Munoz A, Lu M et al. HIV infection, HAART and blood pressure: results from the Multicenter AIDS Cohort Study (MACS). 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract P744].
36. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7: 223-242.
37. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18: 1037-1041.
38. Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608.